Company profile: Portola Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapeutics, discovering and developing treatments for acute and chronic cardiovascular and autoimmune/inflammatory diseases, including PRT054021, an oral factor Xa inhibitor for prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Portola Pharmaceuticals
Sirius Therapeutics
HQ: United States
Website
- Description: Provider of RNAi-based therapies for cardiovascular diseases, developing siRNA therapeutics including SRSD107 targeting coagulation Factor XI (FXI) for prevention and treatment of thromboembolic disorders with potential once- or twice-yearly dosing, and SRSD101 targeting PCSK9 to lower LDL-C for dyslipidemia; leveraging proprietary technology platforms and infrastructure in the US and China.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirius Therapeutics company profile →
Abionyx
HQ: France
Website
- Description: Provider of innovative therapeutic drugs for indications without effective or existing treatments, including rare diseases, with a focus on renal and ophthalmological conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abionyx company profile →
MedAlliance
HQ: Switzerland
Website
- Description: Provider of innovative drug-eluting balloons (DEBs) for treating coronary and peripheral arterial disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedAlliance company profile →
Mirador Biomedical
HQ: United States
Website
- Description: Provider of medical devices that deliver physiological feedback during common procedures, including single-use pressure transducers for distinguishing veins and arteries in central venous catheter insertion, measuring compartment pressure, pleural manometry and pleural pressure monitoring in thoracentesis, measuring opening pressure in lumbar puncture, and Central Venous Pressure monitoring via VA Lock.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirador Biomedical company profile →
Bardy Diagnostics
HQ: United States
Website
- Description: Provider of cardiac monitoring and arrhythmia detection solutions, including the CAM Patch, a lightweight, extended-wear cardiac patch that optimizes P-wave capture for up to 14 days of continuous ECG monitoring; the BDxCONNECT Portal for secure ECG data upload, analysis, and full report delivery; and the CAM Report offering clear, full-disclosure ECG interpretations typically within 48 hours. CAM can be worn during exercise or while showering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bardy Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Portola Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Portola Pharmaceuticals
2.2 - Growth funds investing in similar companies to Portola Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Portola Pharmaceuticals
4.2 - Public trading comparable groups for Portola Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →